(PHILADELPHIA) – Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that ...
Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...
In a new study published in Science Signaling titled, “Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,” researchers from ...
An effective treatment could be found for one of the most aggressive pediatric cancers, alveolar rhabdomyosarcoma (aRMS). These kinds of tumors, which develop mainly in skeletal muscle, are ...
Findings from the LEAP2MONO study support the regulatory submission of venglustat for treatment of type 3 Gaucher disease.
Enzymes are biological catalysts that speed up chemical reactions in living organisms. They are essential for life, as they play a crucial role in various biological processes, such as digestion, ...
High-fat diet (HFD) feeding in mice promotes induction of aldose reductase (AR) activity, expression, and senescence of adipocytes in subcutaneous adipose tissue (scAT), according to a new study in ...
Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...
Everyday Health on MSN
SGLT2 inhibitors and IgAN: Can this diabetes drug delay kidney decline?
Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results